News | February 07, 2025
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
Subscribe To Our Newsletter & Stay Updated
